Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood

Richard R. Ricketts, Robyn M Hatley, Brian J. Corden, Herman Sabio, Charles G Howell

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: The authors describe the use of interferon-alpha-2a (IFN-α- 2a) in the treatment of complex hemangiomas and review the role of interferon (IFN) in this example of an angiogenic disease. Summary Background Data: Hemangiomas are the most frequent tumors of infants and children. They grow rapidly for 6 to 8 months and then resolve over a period of years. Approximately 5% produce life-, sight-, or limb-threatening complications, with mortality rates between 20% and 50%. Aggressive therapy with steroids, arterial ligation or embolization, or surgery has been used in these situations with variable results and high morbidity. Recently, IFN-α was found to be effective treatment in these complex hemangiomas. Methods: Four infants and one child were treated with IFN-α-2a at an initial subcutaneous dose of 1 million units/m2/day and a sustained dose of 3 million units/m2/day for 5 to 11 months. Appropriate laboratory values were monitored and adverse reactions and ultimate response to therapy were recorded. Results: Two patients experienced minor complications that were managed easily. Three patients had total or near-total regression of the hemangioma, one had partial (50%) regression, and one had stabilization but no regression after an average of 7.1 months of IFN therapy. Conclusion: Interferon-α inhibits angiogenesis and endothelial cell migration and proliferation in vitro. The patients in this study add to the growing number who have benefited from IFN therapy. As such, IFN-α should be considered as a first-line agent in treating complex hemangiomas of infants and children.

Original languageEnglish (US)
Pages (from-to)605-614
Number of pages10
JournalAnnals of Surgery
Volume219
Issue number6
DOIs
StatePublished - Jan 1 1994

Fingerprint

Hemangioma
Interferons
Therapeutics
interferon alfa-2a
Cell Movement
Ligation
Extremities
Endothelial Cells
Steroids
Cell Proliferation
Morbidity
Mortality
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. / Ricketts, Richard R.; Hatley, Robyn M; Corden, Brian J.; Sabio, Herman; Howell, Charles G.

In: Annals of Surgery, Vol. 219, No. 6, 01.01.1994, p. 605-614.

Research output: Contribution to journalArticle

Ricketts, Richard R. ; Hatley, Robyn M ; Corden, Brian J. ; Sabio, Herman ; Howell, Charles G. / Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. In: Annals of Surgery. 1994 ; Vol. 219, No. 6. pp. 605-614.
@article{350da02f52444da392e94d523eb04d7e,
title = "Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood",
abstract = "Objective: The authors describe the use of interferon-alpha-2a (IFN-α- 2a) in the treatment of complex hemangiomas and review the role of interferon (IFN) in this example of an angiogenic disease. Summary Background Data: Hemangiomas are the most frequent tumors of infants and children. They grow rapidly for 6 to 8 months and then resolve over a period of years. Approximately 5{\%} produce life-, sight-, or limb-threatening complications, with mortality rates between 20{\%} and 50{\%}. Aggressive therapy with steroids, arterial ligation or embolization, or surgery has been used in these situations with variable results and high morbidity. Recently, IFN-α was found to be effective treatment in these complex hemangiomas. Methods: Four infants and one child were treated with IFN-α-2a at an initial subcutaneous dose of 1 million units/m2/day and a sustained dose of 3 million units/m2/day for 5 to 11 months. Appropriate laboratory values were monitored and adverse reactions and ultimate response to therapy were recorded. Results: Two patients experienced minor complications that were managed easily. Three patients had total or near-total regression of the hemangioma, one had partial (50{\%}) regression, and one had stabilization but no regression after an average of 7.1 months of IFN therapy. Conclusion: Interferon-α inhibits angiogenesis and endothelial cell migration and proliferation in vitro. The patients in this study add to the growing number who have benefited from IFN therapy. As such, IFN-α should be considered as a first-line agent in treating complex hemangiomas of infants and children.",
author = "Ricketts, {Richard R.} and Hatley, {Robyn M} and Corden, {Brian J.} and Herman Sabio and Howell, {Charles G}",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00000658-199406000-00003",
language = "English (US)",
volume = "219",
pages = "605--614",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood

AU - Ricketts, Richard R.

AU - Hatley, Robyn M

AU - Corden, Brian J.

AU - Sabio, Herman

AU - Howell, Charles G

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Objective: The authors describe the use of interferon-alpha-2a (IFN-α- 2a) in the treatment of complex hemangiomas and review the role of interferon (IFN) in this example of an angiogenic disease. Summary Background Data: Hemangiomas are the most frequent tumors of infants and children. They grow rapidly for 6 to 8 months and then resolve over a period of years. Approximately 5% produce life-, sight-, or limb-threatening complications, with mortality rates between 20% and 50%. Aggressive therapy with steroids, arterial ligation or embolization, or surgery has been used in these situations with variable results and high morbidity. Recently, IFN-α was found to be effective treatment in these complex hemangiomas. Methods: Four infants and one child were treated with IFN-α-2a at an initial subcutaneous dose of 1 million units/m2/day and a sustained dose of 3 million units/m2/day for 5 to 11 months. Appropriate laboratory values were monitored and adverse reactions and ultimate response to therapy were recorded. Results: Two patients experienced minor complications that were managed easily. Three patients had total or near-total regression of the hemangioma, one had partial (50%) regression, and one had stabilization but no regression after an average of 7.1 months of IFN therapy. Conclusion: Interferon-α inhibits angiogenesis and endothelial cell migration and proliferation in vitro. The patients in this study add to the growing number who have benefited from IFN therapy. As such, IFN-α should be considered as a first-line agent in treating complex hemangiomas of infants and children.

AB - Objective: The authors describe the use of interferon-alpha-2a (IFN-α- 2a) in the treatment of complex hemangiomas and review the role of interferon (IFN) in this example of an angiogenic disease. Summary Background Data: Hemangiomas are the most frequent tumors of infants and children. They grow rapidly for 6 to 8 months and then resolve over a period of years. Approximately 5% produce life-, sight-, or limb-threatening complications, with mortality rates between 20% and 50%. Aggressive therapy with steroids, arterial ligation or embolization, or surgery has been used in these situations with variable results and high morbidity. Recently, IFN-α was found to be effective treatment in these complex hemangiomas. Methods: Four infants and one child were treated with IFN-α-2a at an initial subcutaneous dose of 1 million units/m2/day and a sustained dose of 3 million units/m2/day for 5 to 11 months. Appropriate laboratory values were monitored and adverse reactions and ultimate response to therapy were recorded. Results: Two patients experienced minor complications that were managed easily. Three patients had total or near-total regression of the hemangioma, one had partial (50%) regression, and one had stabilization but no regression after an average of 7.1 months of IFN therapy. Conclusion: Interferon-α inhibits angiogenesis and endothelial cell migration and proliferation in vitro. The patients in this study add to the growing number who have benefited from IFN therapy. As such, IFN-α should be considered as a first-line agent in treating complex hemangiomas of infants and children.

UR - http://www.scopus.com/inward/record.url?scp=0028332424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332424&partnerID=8YFLogxK

U2 - 10.1097/00000658-199406000-00003

DO - 10.1097/00000658-199406000-00003

M3 - Article

VL - 219

SP - 605

EP - 614

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -